Analytical Data
-
Gene name
HLA-A*02:01&B2M&PRAME(SLLQHLIGL) Tetramer
- Application
-
Alternative Names
PRAME; OIP-4; OIP4; MAPE;
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A140T913 (G25-T305)&P61769
-
Expression Region
A0A140T913 (G25-T305)&P61769 (I21-M119)&SLLQHLIGL
-
Molecular Weight
260-265 kDa under Non reducing (N)
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01/B2M/PRAME (SLLQHLIGL) tetramer is a specialized recombinant protein complex that plays a crucial role in immunological research, particularly in the study of cancer immunotherapies. The HLA-A*02:01 molecule is one of the most commonly expressed major histocompatibility complex (MHC) class I molecules in humans, and it is pivotal for the presentation of antigenic peptides to CD8+ T cells. PRAME (Preferentially Expressed Antigen in Melanoma) is a cancer/testis antigen that is overexpressed in various malignancies, making it a prime target for cancer immunotherapy. The specific peptide SLLQHLIGL, derived from PRAME, is recognized by T cells in the context of HLA-A*02:01, facilitating targeted immune responses against tumor cells. The development of tetramers that combine HLA-A*02:01, β2-microglobulin (B2M), and the PRAME-derived peptide allows for the precise identification and isolation of T cells that are reactive to PRAME, providing insights into immune responses in cancer patients. This tetrameric complex is a powerful tool for tracking T cell responses in both research and clinical settings, offering potential avenues for the design of peptide-based vaccines and adoptive T cell therapies aimed at enhancing anti-tumor immunity. Understanding the dynamics between the tetramer and T cell populations can pave the way for more effective cancer treatment strategies, highlighting the significance of this research in advancing precision medicine.
